Worthington Fore ALS to benefit ALS TDI and MGH
I am Madeline Kennedy, and I am a person with ALS; I was diagnosed in May 2012. You can see my story at www.ConquerALS.com I am also a resident of Worthington Country Club in Bonita Springs, Fl. With the backing of the entire club, we are hosting our third annual golf fundraiser on January 21, 2017. It will have two shotguns, am and pm, and we anticipate 250+ participants. We have raised over $81,500 for ALS research since our first tournament in 2015. Please help us surpass the $100,000 milestone in 2017!
Currently, no one survives ALS. We need research to find a treatment and, eventually, a cure. ALS TDI and MGH give us hope for the future. Every day I fight ALS with every fiber of my being. 90% of pople with ALS die within 2 - 5 years of their diagnois. I am strugging to live past my five-year mark, which will be May 2017. Please consider making an online donation here. Corporate sponsorships are also available. Donations of any amount are most gratefully appreciated.
If you choose to mail your donation, please mention "Worthington" or "Madeline Kennedy" in the memo section of your check. Many thanks!
Half of the proceeds raised will benefit the ALS Therapy Development Institute. The ALS Therapy Development Institute and its scientists actively discover and develop treatments for ALS. The Institute is the world’s first and largest nonprofit biotech focused 100 percent on ALS research. Led by people living with ALS and drug development experts, the charity understands the urgent need to slow and stop this horrible disease. Based in Cambridge, MA, the Institute has served as one of the leaders in sharing data and information with academic and ALS research organizations, people with ALS and their families. For more information, visit www.als.net.
Half of the proceeds raised will benefit the ALS Phase II Fund at Massachusetts General Hospital, home to the largest hospital-based neuroscience research program. It is poised to change the future through their ALS Research Program and the
Multidisciplinary Clinic. These funds will go towards ALS phase II clinical trial process, which is often slowed or stopped in its tracks as MGH searches for funding. Each clinical trial can cost upwards of $500,000 and is totally reliant on philanthropic funding. To avoid delaying trials and allow the process of testing the efficacy of a range of inflammation-reducing drugs, MGH has launched a “Phase II Fund,” set up specifically to provide money as needed for these clinical trials. MGH and its patients are so encouraged by the possibilities these drugs may offer.